KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Income from Non-Controlling Interests: 2011-2018

Historic Income from Non-Controlling Interests for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Dec 2018 value amounting to -$9.8 million.

  • Vertex Pharmaceuticals' Income from Non-Controlling Interests fell 1794.27% to -$25.4 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$9.8 million, marking a year-over-year increase of 94.30%. This contributed to the annual value of -$9.8 million for FY2018, which is 94.30% up from last year.
  • According to the latest figures from FY2018, Vertex Pharmaceuticals' Income from Non-Controlling Interests is -$9.8 million, which was up 94.30% from -$171.8 million recorded in FY2017.
  • In the past 5 years, Vertex Pharmaceuticals' Income from Non-Controlling Interests ranged from a high of $28.0 million in FY2016 and a low of -$171.8 million during FY2017.
  • Over the past 3 years, Vertex Pharmaceuticals' median Income from Non-Controlling Interests value was -$9.8 million (recorded in 2018), while the average stood at -$51.2 million.
  • In the last 5 years, Vertex Pharmaceuticals' Income from Non-Controlling Interests skyrocketed by 187.99% in 2016 and then crashed by 713.29% in 2017.
  • Yearly analysis of 5 years shows Vertex Pharmaceuticals' Income from Non-Controlling Interests stood at -$4.2 million in 2014, then plummeted by 660.07% to -$31.8 million in 2015, then spiked by 187.99% to $28.0 million in 2016, then tumbled by 713.29% to -$171.8 million in 2017, then surged by 94.30% to -$9.8 million in 2018.